NEO-FRADIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Neo-fradin, and what generic alternatives are available?
Neo-fradin is a drug marketed by X Gen Pharms and is included in one NDA.
The generic ingredient in NEO-FRADIN is neomycin sulfate. There are nineteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the neomycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Neo-fradin
A generic version of NEO-FRADIN was approved as neomycin sulfate by XGEN PHARMS on July 28th, 2006.
Summary for NEO-FRADIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 44 |
Patent Applications: | 43 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NEO-FRADIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for NEO-FRADIN
US Patents and Regulatory Information for NEO-FRADIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
X Gen Pharms | NEO-FRADIN | neomycin sulfate | SOLUTION;ORAL | 065010-001 | May 23, 2002 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |